LEXICON PHARMACEUTICALS, INC. 8-K

What Happened Lexicon Pharmaceuticals, Inc. (LXRX) filed an 8‑K on April 30, 2026 reporting results of its annual meeting and related corporate actions. The company filed a Seventh Amended and Restated Certificate of Incorporation (effective April 30, 2026) to increase authorized common shares from 450,000,000 to 900,000,000. At the same time, 408,434.7 shares of Series B Convertible Preferred Stock automatically converted at 50 common shares per preferred into 20,421,735 shares of common stock. The Preferred Stock had been sold in a prior private placement at $65.00 per preferred share; the conversion was effected under the preferred certificate terms and issued under the Section 3(a)(9) exemption.

Key Details

• Automatic conversion: 408,434.7 Series B preferred → 20,421,735 common shares (50-for-1 conversion).
• Equity plan approvals: 2026 Equity Incentive Plan increased from 75,000,000 to 90,000,000 shares; 2026 Non‑Employee Directors’ Plan increased from 4,000,000 to 6,000,000 shares. Both plans’ terms extended until February 12, 2036.
• Authorized shares: Certificate of Incorporation amended to raise authorized common stock from 450,000,000 to 900,000,000 (filed April 30, 2026).
• Vote tallies (April 30, 2026): 2026 Equity Plan approved with 294,995,982 for, 7,116,668 against, 310,512 abstain; 2026 Non‑Employee Directors’ Plan approved with 294,908,842 for, 7,112,300 against, 402,020 abstain. Ernst & Young LLP was ratified as auditor.

Why It Matters These actions increase the company’s available share authorization and the pool of shares that can be granted under equity compensation plans, which can lead to additional potential dilution as awards are granted. The automatic conversion added 20.4 million common shares to the outstanding base without a registered public offering (issued under the Section 3(a)(9) exemption). Investors should note the higher authorized share count and enlarged equity award capacity when evaluating future share count, dilution and executive/director compensation trends.